Celgene Corporation

Philip Chamberlain

Antonia Lopez-Girona

Brian Edwin Cathers

Gang Lu

Mary Matyskiela

Godrej Khambatta

Jeonghoon Sun

Brydon L Bennett

Marilyn Kehry

Kandasamy Hariharan

Henry Chan

Suzana Sturlini Couto

Roli Khattri

Monica Leung

Pilgrim Jackson

Lisa Morrison

Julia Hui

Sanaa Torres

Katherine Stamp

Philip J Sherratt

Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.

Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases

A complex comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN, and uses thereof for identifying therapeutic compounds.

Methods for measuring small molecule affinity to cereblon

A method of screening a cereblon modifying compound for treating a disease or disorder, comprising: obtaining a sample; determining a first protein level of SALL; administering the cereblon modifying compound to the sample; determining a second protein level of SALL; comparing the first level and the second protein level of SALLto determine if the cereblon modifying compound induces degradation of SALL; and selecting the cereblon modifying compound that does not induce degradation of SALL

Methods for screening cereblon modifying compounds

Provided herein are compositions, methods and uses involving antibodies that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.

PD-1 binding proteins and methods of use thereof

Growing community of inventors

San Diego, CA, United States of America

Philip Chamberlain